In a report issued on May 5, Mani Foroohar from SVB Securities reiterated a Buy rating on AlloVir (ALVR – Research Report), with a price target of $30.00. The company’s shares closed last Friday at $4.97, close to its 52-week low of $4.26.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -24.2% and a 31.9% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Arrowhead Pharmaceuticals, and Recursion Pharmaceuticals.
AlloVir has an analyst consensus of Strong Buy, with a price target consensus of $55.00.
See the top stocks recommended by analysts >>
Based on AlloVir’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $57.94 million. In comparison, last year the company had a GAAP net loss of $25.2 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALVR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
- Becton Dickinson (BDX) Gets a Hold Rating from SVB Securities
- SVB Securities Thinks Zymeworks’ Stock is Going to Recover
- SVB Securities Remains a Buy on Turning Point Therapeutics (TPTX)
- Analysts Offer Insights on Healthcare Companies: Nevro Crop (NVRO), BeiGene (BGNE) and Provention Bio (PRVB)
- SVB Securities Issues a Hold Rating on Blueprint Medicines (BPMC)
